Vertex Pharmaceuticals Inc. closed $106.51 short of its 52-week high ($519.88), which the company reached on November 8th.

In a report released today, Gena Wang from Barclays maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price ...

In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.

The company's collaboration partner, Vertex Pharmaceuticals(NASDAQ: VRTX), made progress activating authorized treatment centers capable of administrating Casgevy, but CRISPR still hasn't reported any ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor ...

I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

December 10, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor and Analyst Day in Boston today. The event will feature presentations from Ligand CEO Todd Davis ...

Vertex has appointed a new commercial head for ex-US activites, as the company aims to resolve its two-year row with UK health officials over the price of its cystic fibrosis drugs.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...